



Zanidatamab ASCO GI Webcast

5:00PM ET (2:00PM PT)

NYSE: ZYME

www.zymeworks.com

Zanidatamab ASCO Gastrointestinal Cancers Symposium Webcast



Dr. Diana Hausman, MD

Chief Medical Officer
Zymeworks



Melinda Bachini

Director of Advocacy
Cholangiocarcinoma Foundation






cholangiocarcinoma
FOUNDATION®

The Most Pressing Unmet Clinical Needs in CCA,
from a Patient Perspective

January 15, 2021

Melinda Bachini, Director of Advocacy

CHOLANGIO...WHAT???



Access

- To experts
- To biomarker testing
- To clinical trials
- To treatment




Asking the patients what they think.....

- Earlier and better diagnostics. Specialists in cholangiocarcinoma
- Resources immediately after diagnosis explaining CCA, CCF, treatments, clinical trials, etc...
- Educating primary care doctors, PA's, NP's
- Awareness of this disease
- Better treatments
- Timely results following scans
- Standard protocol for monitoring with scans and bloodwork, that insurance will cover
- Understanding Risk factors.....many patients have none of the listed risks
- Financial barriers/burdens


Patients want a provider who thinks outside the box

- Patients are not impressed with standard of care options
- Clinical trials immediately
- Precision medicine personalized for each patient

Q25 Would you view **molecular profiling** (testing of tumor tissue to look for specific changes in the cells) of your cancer as an important and necessary part of your overall treatment plan?



Q40 Are you willing to participate in a clinical trial?




CCF is...

- Advocate
- Convener
- Connector
- Funder




SPECIALIST MAP




Physicians and organizations that
have high clinical, scientific and
industry experience

Viewed more than 11,500 times

BIOMARKERSMATTER.ORG



CCA Specific Version



Tumor Agnostic Version



Provider Version

ciitizen



Patient consent



Gather patient data



Mobile summary



Clinical trial finder

CCF INFORMATION SHARED THROUGH

- Patient Advisory Boards
- Patient Support Groups
- Caregiver Support Groups
- Webinars
- Clinical Trial Sharing





LIVE AND ON-DEMAND

cholangiocarcinoma foundation

ANNUAL CONFERENCE

MARCH 31 - APRIL 2, 2021




Dr. Diana Hausman, MD

Chief Medical Officer
Zymeworks

Zanidatamab Monotherapy Anti-Tumor Activity in BTC

Data supports pivotal trial now enrolling in 2L BTC (HERIZON-BTC-01; NCT04466891)




E = Extrahepatic Cholangiocarcinoma, FISH = fluorescence in situ hybridization; I = Intrahepatic Cholangiocarcinoma; IHC = immunohistochemistry; G = Gallbladder; T = trastuzumab; Trt = treatment. Response-evaluable: all treated patients with measurable disease who had at least one evaluable, post-baseline disease assessment (per RECIST 1.1) or discontinued study treatment due to death or clinical progression. Note: One patient was not response evaluable because they withdrew from the study. One patient in the response-evaluable set died prior to the post-baseline tumor measurement and is not included in the plot (counted as PD). Data snapshot from unlocked database 16 November 2020 and subject to change.



TIP: A Phase 2b Study of Zanidatamab (ZW25) Monotherapy in Patients with HER2-amplified Biliary Tract Cancer (BTC): HERIZON-BTC-01 Study


ZW25-203 Study Design & Key Endpoints



AE = adverse event; CT = computed tomography scan; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; IV = intravenous; MRI = magnetic resonance imaging; SAE = serious adverse event.
* for tumor assessment per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1.


Zanidatamab Monotherapy Anti-tumor Activity in GEA

Median 3 prior systemic regimens, including prior trastuzumab in most patients



Addition of Chemo to Zanidatamab Increases Response in GEA

Promising activity seen in patients with FISH+ and FISH- disease





Dr. Funda Meric-Bernstam, MD

Department of Investigational Cancer Therapeutics,
Division of Cancer Medicine
UT MD Anderson Cancer Center, TX



James Priour, MBA

Senior Vice President, Commercial
Zymeworks

Zanidatamab ASCO Gastrointestinal Cancers Symposium Webcast



Dr. Ali Tehrani, PhD

President & CEO
Zymeworks